

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Fordyce Marshall</u>  (Last) (First) (Middle) C/O VERA THERAPEUTICS, INC. 2000 SIERRA POINT PARKWAY, SUITE 1200  (Street) BRISBANE CA 94005  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Vera Therapeutics, Inc. [ VERA ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>PRESIDENT AND CEO</b>
	3. Date of Earliest Transaction (Month/Day/Year) 11/25/2024	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Common Stock	11/25/2024		M		6,579	A	\$2.8968	92,521	D	
Class A Common Stock	11/25/2024		S <sup>(1)</sup>		6,579	D	\$47.0485 <sup>(2)</sup>	85,942	D	
Class A Common Stock	11/25/2024		M		7,665	A	\$2.8968	93,607	D	
Class A Common Stock	11/25/2024		S <sup>(1)</sup>		7,665	D	\$48.1839 <sup>(3)</sup>	85,942	D	
Class A Common Stock	11/25/2024		M		1,381	A	\$2.8968	87,323	D	
Class A Common Stock	11/25/2024		S <sup>(1)</sup>		1,381	D	\$48.8042 <sup>(4)</sup>	85,942	D	
Class A Common Stock	11/25/2024		M		1,875	A	\$2.8968	87,817	D	
Class A Common Stock	11/25/2024		S <sup>(1)</sup>		1,875	D	\$48.76	85,942	D	
Class A Common Stock	11/25/2024		M		1,875	A	\$2.8968	87,817	D	
Class A Common Stock	11/25/2024		S <sup>(1)</sup>		1,875	D	\$49	85,942	D	
Class A Common Stock								222,030	I	By GRAT

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$2.8968	11/25/2024		M			15,625	(5)	12/15/2030	Class A Common Stock	15,625	\$0	722,962	D	
Stock Option (Right to Buy)	\$2.8968	11/25/2024		M			1,875	(5)	12/15/2030	Class A Common Stock	1,875	\$0	721,087	D	
Stock Option (Right to Buy)	\$2.8968	11/25/2024		M			1,875	(5)	12/15/2030	Class A Common Stock	1,875	\$0	719,212	D	

**Explanation of Responses:**

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
- The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$46.59 to \$47.55, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$47.59 to \$48.58, inclusive. The Reporting Person will provide upon request to the staff

of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

4. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$48.59 to \$49.27, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

5. 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.

/s/ Joseph R. Young, Attorney-  
in-Fact 11/27/2024

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**